Chester County News and Community Website
CHADDS FORD, PA — ClariMed, Inc. has announced that Louisa Harvey, Principal and Founder of ClariMed, will serve as a judge for the prestigious Pharmapack Awards 2025. This appointment highlights ClariMed’s …
ClariMed’s Louisa Harvey Appointed Judge for Pharmapack Awards 2025 Read More
BERWYN, PA — AscellaHealth has unveiled its latest Specialty & Rare Pipeline Digest™ for the second quarter of 2024. This quarterly publication is known for its extensive coverage of new, …
AscellaHealth Releases Quarterly Specialty & Rare Pipeline Digest Read More
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has filed a new composition of matter patent with the U.S. Patent and Trademark Office. This patent covers novel crystalline forms of …
Annovis Bio Files Patent for New Crystal Form of Buntanetap Read More
WASHINGTON, D.C. — The Food and Drug Administration (FDA) has approved the first generic version of the animal drug Temaril-P, offering a new option for pet owners and veterinarians. Trimeprazine …
FDA Approves First Generic Animal Drug for Itching and Cough Relief in Dogs Read More
PARSIPPANY, NJ & KING OF PRUSSIA, PA — Ferring Pharmaceuticals has teamed up with SK pharmteco to scale up the commercial manufacturing capacity of ADSTILADRIN (nadofaragene firadenovec-vncg), a gene therapy …
Ferring Pharmaceuticals Partners with SK pharmteco to Boost Gene Therapy Supply Read More
RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) recently announced its decision to proceed with the Phase 3 RAISE trial of intravenous (IV) ganaxolone for treating refractory status epilepticus (RSE), …
Marinus Pharmaceuticals Continues Phase 3 Trial for Epilepticus Treatment Despite Setback Read More BERWYN, PA — AscellaHealth, a leading specialty pharmaceutical partner, has been recognized for the third consecutive year as one of “Americas’ Fastest Growing Companies” by The Financial Times. This prestigious …
AscellaHealth Named Among Fastest Growing Companies by The Financial Times for Third Year Read More
PHILADELPHIA, PA — Carisma Therapeutics Inc. (NASDAQ: CARM) recently disclosed its financial results for the fourth quarter and the full year concluding on December 31, 2023, outlining a plan to …
Carisma Therapeutics Concentrates on Promising CT-0525, Restructures to Manage Finances amid 2023 Losses Read More
RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a biopharmaceutical company focused on the development of innovative therapies for complex medical conditions, recently unveiled its financial outcomes for the quarter …
NRx Pharmaceuticals Charts New Path with Strategic Milestones and Cost Reductions Read More PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM), a trailblazer in engineered macrophage development for immunotherapies, announced a significant transition in its leadership team. Effective April 1, 2024, John Hohneker, …
Carisma Therapeutics Welcomes New Board Member John Hohneker Amid Company Evolution Read More